WO2011102640A2 - Method for preparing sitagliptin and amine salt intermediates used therein - Google Patents
Method for preparing sitagliptin and amine salt intermediates used therein Download PDFInfo
- Publication number
- WO2011102640A2 WO2011102640A2 PCT/KR2011/001024 KR2011001024W WO2011102640A2 WO 2011102640 A2 WO2011102640 A2 WO 2011102640A2 KR 2011001024 W KR2011001024 W KR 2011001024W WO 2011102640 A2 WO2011102640 A2 WO 2011102640A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- compound
- reaction
- mixture
- Prior art date
Links
- -1 amine salt Chemical class 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 25
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 title claims abstract description 23
- 229960004034 sitagliptin Drugs 0.000 title claims abstract description 23
- 239000000543 intermediate Substances 0.000 title abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 34
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 18
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- BRLQWZUYTZBJKN-GSVOUGTGSA-N (+)-Epichlorohydrin Chemical compound ClC[C@@H]1CO1 BRLQWZUYTZBJKN-GSVOUGTGSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 238000006482 condensation reaction Methods 0.000 claims description 4
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 150000004794 vinyl magnesium halides Chemical class 0.000 claims description 4
- 238000006886 vinylation reaction Methods 0.000 claims description 4
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 3
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000006735 epoxidation reaction Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 claims description 3
- 238000001465 metallisation Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 239000012286 potassium permanganate Substances 0.000 claims description 3
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 claims description 2
- FMTDZGCPYKWMPT-UHFFFAOYSA-N 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1NCCN2C(C(F)(F)F)=NN=C21 FMTDZGCPYKWMPT-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- 229910019093 NaOCl Inorganic materials 0.000 claims description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N p-toluenesulfonyl chloride Substances CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 2
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 1
- 229940093499 ethyl acetate Drugs 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 claims 1
- QIFIFJAHETUWOT-ZCFIWIBFSA-N (3r)-3-azido-4-(2,4,5-trifluorophenyl)butanoic acid Chemical compound OC(=O)C[C@H](N=[N+]=[N-])CC1=CC(F)=C(F)C=C1F QIFIFJAHETUWOT-ZCFIWIBFSA-N 0.000 abstract description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 14
- 230000003287 optical effect Effects 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- SZVCSGIDOASKJG-MRVPVSSYSA-N (2r)-1-(2,4,5-trifluorophenyl)pent-4-en-2-ol Chemical compound C=CC[C@@H](O)CC1=CC(F)=C(F)C=C1F SZVCSGIDOASKJG-MRVPVSSYSA-N 0.000 description 4
- RLPWKAAOCAHQKV-QMMMGPOBSA-N 1-[(2s)-2-azidopent-4-enyl]-2,4,5-trifluorobenzene Chemical compound FC1=CC(F)=C(C[C@H](CC=C)N=[N+]=[N-])C=C1F RLPWKAAOCAHQKV-QMMMGPOBSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000003747 Grignard reaction Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- WZLOKEZFZKLWIH-LURJTMIESA-N (2s)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol Chemical compound ClC[C@@H](O)CC1=CC(F)=C(F)C=C1F WZLOKEZFZKLWIH-LURJTMIESA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- IEMQWKLTOZPCQF-FCXZQVPUSA-N (3R)-3-azido-4-(2,4,5-trifluorophenyl)butanoic acid 2,2-diphenylethanamine Chemical compound NCC(C1=CC=CC=C1)C1=CC=CC=C1.OC(=O)C[C@@H](CC1=C(F)C=C(F)C(F)=C1)N=[N+]=[N-] IEMQWKLTOZPCQF-FCXZQVPUSA-N 0.000 description 1
- DJCSLVLMXQZBHQ-SECBINFHSA-N (3r)-3-azido-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one Chemical compound C1=C(F)C(F)=CC(F)=C1C[C@@H](N=[N+]=[N-])CC(=O)N1CC2=NN=C(C(F)(F)F)N2CC1 DJCSLVLMXQZBHQ-SECBINFHSA-N 0.000 description 1
- AUJSFJXDHMABLJ-UHFFFAOYSA-N 1,2,4-trifluorobenzene hydrobromide Chemical compound Br.FC1=CC=C(F)C(F)=C1 AUJSFJXDHMABLJ-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- GAUXEYCSWSMMFZ-UHFFFAOYSA-N 1-(bromomethyl)-2,4,5-trifluorobenzene Chemical compound FC1=CC(F)=C(CBr)C=C1F GAUXEYCSWSMMFZ-UHFFFAOYSA-N 0.000 description 1
- JMXPOOVDUVHJRO-UHFFFAOYSA-N 1-(chloromethyl)-2,4,5-trifluorobenzene Chemical compound FC1=CC(F)=C(CCl)C=C1F JMXPOOVDUVHJRO-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- YDVDOSPFIMKVNT-WDZFZDKYSA-N C=C1C(C/C(/O)=C/C(CC(C(F)=CC2)F)=C2F)C1 Chemical compound C=C1C(C/C(/O)=C/C(CC(C(F)=CC2)F)=C2F)C1 YDVDOSPFIMKVNT-WDZFZDKYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229910000424 chromium(II) oxide Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- GDTRAYDPXKZJGD-UHFFFAOYSA-N dichlorophosphoryl hypochlorite Chemical compound ClOP(Cl)(Cl)=O GDTRAYDPXKZJGD-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- VASIZKWUTCETSD-UHFFFAOYSA-N manganese(II) oxide Inorganic materials [Mn]=O VASIZKWUTCETSD-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical group O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical group [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960004115 sitagliptin phosphate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a method for preparing sitagliptin in a high yield and purity, which is used as adjurvants for diet and exercise therapies of Il-type protein patients, and amine salt intermediates used therein.
- Sitagliptin of formula (I) is a drug which selectively inhibits second generation dipeptidyl peptidase IV (DPP-4), making an incretin level in the body constant.
- DPP-4 dipeptidyl peptidase IV
- a phosphate monohydrate form of sitagliptin has been approved as adjurvants for diet and exercise therapies of Il-type protein patients by FDA dated October, 2006, and it is currently commercially marketable as a trade name of JanuviaTM (single preparation) or JanumetTM (oral complex preparation with metformine) in Korea or United States of America.
- this method has problems in that it requires a further purification of sitagliptin in the final step to control a stereoselectivity and highten an optical purity, and that a yield in the purification process is very low, i.e., 72%.
- a method for preparing sitagliptin which comprises the steps of:
- R 1 , R 2 and R 3 are each independently H, C 1 -5 alkyl, benzyl, 1- phenylethyl, or 2,2-diphenylethyl; or linked together with the adjacent nitrogen atom to form a pyridine, piperidine, morpholine, pyrrolidine, or piperazine ring.
- R 1 , R 2 and R 3 have the same meanings as defined above. Best Mode for Carrying Out the Invention
- the method for preparing sitagliptin according to the present invention is characterized by the use of an amine salt of (3R)-3-azido-4-(2,4,5- trifluorophenyl)-butyric acid (formula (V)), which can be formed in high compound and optical purities, as an intermediate.
- sitagliptin of formula (I) of the present invention may be prepared by the procedure shown in Reaction Scheme B, which is explained below in more detail.
- X is halogen
- L is mesyl, tosyl, benzenesulfonyl or trifluoromethanesulfonyl
- R is linear or branched C 1-5 alkyl
- (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II) may be prepared from a 2,4,5-trifluorobenzyl halide by sequentially performing a Grignard reaction, a reaction with (S)-epichlorohydrin, epoxidation, and vinylation.
- a 2,4,5-trifluorobenzyl halide is subjected to organic metallization (a Grignard reaction) to obtain an organic metalide, which is sequentially subjected to respective reactions with a copper halide (CuX, a catalyst content) and (S)-epichlorohydrin, to obtain (2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2- propanol.
- organic metallization a Grignard reaction
- the organic metallization may be performed by subjecting a 2,4,5-trifluorobenzyl halide to a reaction with magnesium (Mg) and an organic alkyl halide such as 1,2-dibromoethane, a reaction with magnesium (Mg) and iodine (I 2 ), or a reaction with isopropyl magnesium chloride (z- PrMgCl).
- the 2,4,5-trifluorobenzyl halide may be 2,4,5-trifluorobenzyl bromide, 2,4,5-trifluorobenzyl chloride, or a mixture thereof.
- the copper halide used in this reaction may be Cul, CuBr, CuBrS(CH 3 ) 2 , or a mixture thereof.
- step la (2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2-propanol obtained in step la is subjected to an epoxidation reaction using a strong base in an organic solvent to obtain (2S)-2-(2,4,5-trifluorobenzyl)-oxylane.
- the organic solvent used in this reaction may be tetrahydrofuran, diethyl ether, or a mixture thereof
- the strong base used in this reaction may be a hydroxide of an alkali metal such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof, preferably sodium hydroxide.
- Step lc (2S)-2-(2,4,5-trifluorobenzyl)-oxylane obtained in step lb is subjected to a vinylation reaction with a vinyl magnesium halide to obtain (2R)- l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II) having the vinyl group at its end.
- the vinyl magnesium halide may be vinyl magnesium bromide, vinyl magnesium chloride, or a mixture thereof.
- the vinylation reaction may be performed in an organic solvent such as tetrahydrofuran, diethyl ether, and a mixture thereof, and in the presence of a copper halide catalyst such as Cul, CuBr, CuBrS(CH 3 ) 2 , and a mixture thereof.
- the reaction in step lc may be conducted after or without removing an organic solvent from the resulting solution generated in step lb. Preferably, it may be continuously conducted without removal of the organic solvent used in step lb due to high volatility of (2S)-2-(2,4,5-trifluorobenzyl)-oxylane, which leads to reproducible formation of (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II).
- (2S)-l-(2-azido-4-pentenyl)-2,4,5-trifluorobenzene of formula (III) having an azido group may be prepared by subjecting (2R)-1 -(2,4,5- trifiuorophenyl)-4-penten-2-ol of formula (II) obtained in step 1 to a reaction with an activating agent to activate its hydroxy group, followed by an azidation reaction.
- the activating agent used in this reaction may be mesyl chloride, -tosyl chloride, benzenesulfonyl chloride, trifluoromethanesulfonyl chloride, or a mixture thereof.
- the azidation reaction may be carried out by using a compound having an azido group such as sodium azide.
- step 3 (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (IV) having a carboxy group may be prepared by subjecting (2S)-l-(2-azido-4- pentenyl)-2,4,5-trifluorobenzene of formula (III) obtained in step 2 to an oxidation reaction with an oxidizing agent to oxidize the alkenyl group therein.
- the oxidizing agent used in this reaction may be NaIO 4 , NaMnO , KMnO 4 , H 2 CrO , OsO 4 , NaOCl, or a mixture thereof.
- the oxidizing agent may be preferably used in an amount ranging from 1 to 5 mole equivalents based on the amount of the compound of formula (III).
- the reaction in step 3 is conducted in the presence of a catalyst, wherein suitable for use as the catalyst is RuCl 3 , RuO 4 , OsO 4 , MnO , or a mixture thereof.
- the catalyst may be preferably used in an amount ranging from 0.0001 to 0.1 mole equivalents based on the amount of the compound of formula (III).
- an amine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (V) may be prepared by subjecting (3R)-3-azido-4-(2,4,5- trifluorophenyl)-butyric acid of formula (IV) obtained in step 3 to a reaction with an amine, i.e., NR J R 2 R 3 .
- the amine, NR'R 2 R 3 may be a first, secondary or tertiary amine, and representative examples thereof include benzylamine, (R) or (S)- methylbenzylamine, 2,2-diphenylethylamine, dibenzylamine, dicyclohexylamine, diisopropylamine, diisopropylethylamine, diphenylamine, triethylamine, pyridine, and morpholine. It may be preferably used in an amount ranging from 0.8 to 10 mole equivalents based on the amount of the compound of formula (IV).
- the crystallization may be carried out in an organic solvent selected from the group consisting of toluene, ethyl acetate, n-hexane, methylbutylether, heptane, and a mixture thereof.
- (3 R)- 3 -azido- 1 - (3 -trifluoromethyl- 5,6- dihydi [ 1 ,2,4]triazolo[4,3-a]pyrazin-7-yl)-4-(2,4,5-trifluorophenyl)-butan- 1 -one of formula (VI) may be prepared by subjecting the amine salt of (3R)-3-azido-4- (2,4,5-trifluorophenyl)-butyric acid of formula (V) obtained in step 4 to a condensation reaction with 3-trifluoromethyl-5,6,7,8-tetrahydro- [l,2,4]triazolo[4,3-a]pyrazine (TFT).
- TFT 3-trifluoromethyl-5,6,7,8-tetrahydro- [l,2,4]triazolo[4,3-a]pyrazine
- the compound of formula (V) is further allowed to be kept in the presence of an lw3 ⁇ 4anrc o ⁇ r ⁇
- resulting compound is subjected to a reaction with a carboxy group-activating agent to activate the carboxy group therein.
- the inorganic acid may be hydrochloride, nitric acid, sulfuric acid, phosphoric acid, or a mixture thereof, and the organic acid may be formic acid, acetic acid, tartaric acid, benzenesulfonic acid, toluenesulfonic acid, or a mixture thereof.
- exemplary carboxy group-activating agents include thionylchloride, oxalylchlori.de, phosphoryloxychloride, N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide (EDC), N,N'-dicyclohexylcarbodiimide (DCC), l,l"-carbonyldiimidazole (CDI), a mixture of DCC and 1- hydroxybenzotriazole (HOBt), a mixture of DCC and 1-hydroxysuccinimide, and a mixture thereof.
- EDC N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide
- DCC N,N'-dicyclohexylcarbodiimide
- CDI l,l"-carbonyldiimidazole
- HOBt hydroxybenzotriazole
- sitagliptin of formula (I) may be prepared by subjecting (3R)- 3-azido- 1 -(3-trifluoromethyl-5,6-dihydro-8H-[ 1 ,2,4]triazolo[4,3-a]pyrazin-7- yl)-4-(2,4,5-trifluorophenyl)-butan-l-one of formula (VI) obtained in step 5 to a reduction reaction with a reducing agent to reduce the azido group therein.
- the reducing agent used in this reaction may be PPh 3 /H 2 O, PPh 3 /HCl, PPh 3 /NH 4 OH, PPh 3 /H 2 S, or a mixture thereof.
- a metal catalyst including Ranie-Ni, Pd, Pt, Pd/C, Pd/Al 2 O 3 , Pd(OH) 2 /C, and a mixture thereof, it may be used as the reducing agent hydrogen, HCOOH, (NH 4 )O 2 H, NH 2 NH 2 , BH 3 , NaBH 4 , Zn, HCl, or a mixture thereof.
- the title compound, sitagliptin, thus obtained may be converted to a form of phosphate through a further reaction with phosphoric acid.
- a conventional sitagliptin preparation method requires a further purification of sitagliptin in order to improve both compound purity and optical purity, which disadvantageously causes a significant decrease of a yield.
- the inventive method employs as an intermediate an amine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric a ⁇ _ (formula ⁇ (V)) which ⁇ can be formedin a high compound purity-(e . g . , 98%)- and a high optical purity (e.g., 99.8% ee), thereby simply and economically generating desired sitagliptin in a high yield and purity without an additional purification.
- amine salt of formula (V) used as an intermediate in the preparation of sitagliptin according to the present invention is a novel compound.
- Preferred amine salt intermediates include (R)-methylbenzylamine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (Va) and (S)- methylbenzylamine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (Vb):
- sitagliptin can be easily prepared in a high yield and purity.
- Example 1 Preparation of l-chloro-3-(2,4,5-trifluorophenyl)-(2S)-propanol
- the organic layer was separated, sequentially washed with 24mL of IN HC1 and 120mL of water, washed twice with 240mL of brine, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure.
- Step 3-1 The residue obtained in Step 3-1 was dissolved in 120mL of DMF, which was mixed with 9.58g of NaN 3 dissolved in 36mL of water. The mixture was heated to 75 ° C and stirred for 2 hrs. After the completion of the reaction was confirmed by TLC, the reaction solution was cooled to room temperature. 240mL of water and 120mL of n-hexane were added to the resulting solution. The organic layer was separated, washed twice with 240mL of water, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 25.3g of the title compound (yield: 94%).
- the organic layer was separated and extracted with lOOmL of EA.
- the organic solvent was removed from the extract under a reduced pressure.
- the resulting resiude was dissolved in 250mL of EA, which was washed three times with 250mL of water.
- the organic layer was dried over anhydrous magnesium sulfate, and filtered.
- the organic solvent was removed from the filtrate under a reduced pressure to obtain 26.2g of the title compound (yield: 98%, purity: 82%, optical purity: 96.6% ee).
- optical purity: 96.6% ee prepared in Example 4 was added dropwise to 7.5mL of EA. 2.24mL of dibenzylamine was slowly added thereto over 15 min and stirred for 10 min. 22.5mL of n-hexane was slowly added to the resulting solution to generate a solid precipitate. After 1 hr, the precipitate was separated by filtration and dried with a warm breeze in a 40 ° C oven for 12 hrs to obtain 4.1g of the title compound (yield: 78%, purity: 98.5%, optical purity: 98.0% ee).
- Step 8-1 12.0mL of thionyl chloride and 0.64mL of DMF were added to the resulting solution obtained in Step 8-1, which was refluxed for 3 hrs. After the completion of the reaction was confirmed by NMR, the remaining amouts of thionyl chloride and the organic solvent were removed from the resulting solution under a reduced pressure.
- Step 8-2 The residue obtained in Step 8-2 was dissolved in lOOmL of MC, which was slowly added dropwise to 100ml of a saturated sodium bicarbonate solution containing 1 1.4g of 3-trifluoromethyl-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3- ajpyrazine hydrochloride at below 10 ° C, and stirred at room temperature for 1 nr. The water layer was removed from the resulting solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 33.8g of the title compound (yield: 95%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a method for preparing sitagliptin by using an amine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid (formula (V)) in a high yield and purity, and amine salt intermediates used therein.
Description
Description
Title of Invention METHOD FOR PREPARING SITAGLIPTI AND AMINE SALT
INTERMEDIATES USED THEREIN
Technical Field The present invention relates to a method for preparing sitagliptin in a high yield and purity, which is used as adjurvants for diet and exercise therapies of Il-type protein patients, and amine salt intermediates used therein.
Background Art
Sitagliptin of formula (I) is a drug which selectively inhibits second generation dipeptidyl peptidase IV (DPP-4), making an incretin level in the body constant. A phosphate monohydrate form of sitagliptin has been approved as adjurvants for diet and exercise therapies of Il-type protein patients by FDA dated October, 2006, and it is currently commercially marketable as a trade name of Januvia™ (single preparation) or Janumet™ (oral complex preparation with metformine) in Korea or United States of America.
Various methods of preparing sitagliptin are hitherto reported. For example, International Publication No. WO 2005/097733 discloses a method of preparing sitagliptin by way of stereoselectively reducing an enamine intermediate using a rodium catalyst of [Rh(cod)Cl]2 and a chiral diphosphine ligand, as shown in Reaction Scheme A.
[Reaction Scheme A]
However, this method has problems in that it requires a further purification of sitagliptin in the final step to control a stereoselectivity and highten an optical purity, and that a yield in the purification process is very low, i.e., 72%.
Disclosure of Invention
Accordingly, it is an object of the present invention to provide an effective method for preparing sitagliptin in a high yield and purity, and intermediates used therein.
In accordance with one aspect of the present invention, there is provided
a method for preparing sitagliptin, which comprises the steps of:
(a) subjecting the compound of formula (IV) to a reaction with an amine of NR R R to obtain an amine salt of formula (V); and
(b) subjecting the amine salt of formula (V) to a condensation reaction with 3-trifluoromethyl-5,6,7,8-tetrahydro-[ 1 ,2,4]triazolo[4,3-a]pyrazine
(TFT), followed by reduction of the azido group in the resulting compound:
R1, R2 and R3 are each independently H, C1 -5 alkyl, benzyl, 1- phenylethyl, or 2,2-diphenylethyl; or linked together with the adjacent nitrogen atom to form a pyridine, piperidine, morpholine, pyrrolidine, or piperazine ring.
In accordance with another aspect of the present invention, there is provided a compound of formula (V) used as an intermediate in preparing sitagliptin:
R1, R2 and R3 have the same meanings as defined above.
Best Mode for Carrying Out the Invention
The method for preparing sitagliptin according to the present invention is characterized by the use of an amine salt of (3R)-3-azido-4-(2,4,5- trifluorophenyl)-butyric acid (formula (V)), which can be formed in high compound and optical purities, as an intermediate.
The sitagliptin of formula (I) of the present invention may be prepared by the procedure shown in Reaction Scheme B, which is explained below in more detail.
[Reaction Scheme B]
wherein,
X is halogen;
L is mesyl, tosyl, benzenesulfonyl or trifluoromethanesulfonyl;
R is linear or branched C1-5 alkyl; and
R1, R2 and R3 have the same meanings as defmed above.
<Step 1>
In step 1, (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II) may be prepared from a 2,4,5-trifluorobenzyl halide by sequentially performing a Grignard reaction, a reaction with (S)-epichlorohydrin, epoxidation, and vinylation.
— Step-l-a>
First, a 2,4,5-trifluorobenzyl halide is subjected to organic metallization (a Grignard reaction) to obtain an organic metalide, which is sequentially subjected to respective reactions with a copper halide (CuX, a catalyst content) and (S)-epichlorohydrin, to obtain (2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2- propanol.
The organic metallization (the Grignard reaction) may be performed by subjecting a 2,4,5-trifluorobenzyl halide to a reaction with magnesium (Mg) and an organic alkyl halide such as 1,2-dibromoethane, a reaction with magnesium (Mg) and iodine (I2), or a reaction with isopropyl magnesium chloride (z- PrMgCl). The 2,4,5-trifluorobenzyl halide may be 2,4,5-trifluorobenzyl bromide, 2,4,5-trifluorobenzyl chloride, or a mixture thereof.
The copper halide used in this reaction may be Cul, CuBr, CuBrS(CH3)2, or a mixture thereof.
<Step lb>
Then, (2S)-3-(2,4,5-trifluorophenyl)-l-chloro-2-propanol obtained in step la is subjected to an epoxidation reaction using a strong base in an organic solvent to obtain (2S)-2-(2,4,5-trifluorobenzyl)-oxylane.
The organic solvent used in this reaction may be tetrahydrofuran, diethyl ether, or a mixture thereof, and the strong base used in this reaction may be a hydroxide of an alkali metal such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof, preferably sodium hydroxide.
<Step lc>
Then, (2S)-2-(2,4,5-trifluorobenzyl)-oxylane obtained in step lb is subjected to a vinylation reaction with a vinyl magnesium halide to obtain (2R)- l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II) having the vinyl group at its end.
The vinyl magnesium halide may be vinyl magnesium bromide, vinyl magnesium chloride, or a mixture thereof. Preferably, the vinylation reaction may be performed in an organic solvent such as tetrahydrofuran, diethyl ether, and a mixture thereof, and in the presence of a copper halide catalyst such as Cul, CuBr, CuBrS(CH3)2, and a mixture thereof.
The reaction in step lc may be conducted after or without removing an organic solvent from the resulting solution generated in step lb. Preferably, it may be continuously conducted without removal of the organic solvent used in step lb due to high volatility of (2S)-2-(2,4,5-trifluorobenzyl)-oxylane, which leads to reproducible formation of (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol of formula (II).
<Step 2>
In step 2, (2S)-l-(2-azido-4-pentenyl)-2,4,5-trifluorobenzene of formula (III) having an azido group may be prepared by subjecting (2R)-1 -(2,4,5- trifiuorophenyl)-4-penten-2-ol of formula (II) obtained in step 1 to a reaction with an activating agent to activate its hydroxy group, followed by an azidation reaction.
The activating agent used in this reaction may be mesyl chloride, -tosyl chloride, benzenesulfonyl chloride, trifluoromethanesulfonyl chloride, or a mixture thereof.
The azidation reaction may be carried out by using a compound having an azido group such as sodium azide. <Step 3>
In step 3, (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (IV) having a carboxy group may be prepared by subjecting (2S)-l-(2-azido-4-
pentenyl)-2,4,5-trifluorobenzene of formula (III) obtained in step 2 to an oxidation reaction with an oxidizing agent to oxidize the alkenyl group therein.
The oxidizing agent used in this reaction may be NaIO4, NaMnO , KMnO4, H2CrO , OsO4, NaOCl, or a mixture thereof. The oxidizing agent may be preferably used in an amount ranging from 1 to 5 mole equivalents based on the amount of the compound of formula (III).
It is preferred that the reaction in step 3 is conducted in the presence of a catalyst, wherein suitable for use as the catalyst is RuCl3, RuO4, OsO4, MnO , or a mixture thereof. The catalyst may be preferably used in an amount ranging from 0.0001 to 0.1 mole equivalents based on the amount of the compound of formula (III).
<Step 4> In step 4, an amine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (V) may be prepared by subjecting (3R)-3-azido-4-(2,4,5- trifluorophenyl)-butyric acid of formula (IV) obtained in step 3 to a reaction with an amine, i.e., NRJR2R3.
The amine, NR'R2R3, may be a first, secondary or tertiary amine, and representative examples thereof include benzylamine, (R) or (S)- methylbenzylamine, 2,2-diphenylethylamine, dibenzylamine, dicyclohexylamine, diisopropylamine, diisopropylethylamine, diphenylamine, triethylamine, pyridine, and morpholine. It may be preferably used in an amount ranging from 0.8 to 10 mole equivalents based on the amount of the compound of formula (IV).
After the reaction with the amine, induction of crystallization may be performed. The crystallization may be carried out in an organic solvent selected from the group consisting of toluene, ethyl acetate, n-hexane, methylbutylether, heptane, and a mixture thereof.
<Step 5>
(3 R)- 3 -azido- 1 - (3 -trifluoromethyl- 5,6- dihydi
[ 1 ,2,4]triazolo[4,3-a]pyrazin-7-yl)-4-(2,4,5-trifluorophenyl)-butan- 1 -one of formula (VI) may be prepared by subjecting the amine salt of (3R)-3-azido-4- (2,4,5-trifluorophenyl)-butyric acid of formula (V) obtained in step 4 to a condensation reaction with 3-trifluoromethyl-5,6,7,8-tetrahydro- [l,2,4]triazolo[4,3-a]pyrazine (TFT).
It is preferred that prior to the condensation reaction with TFT, the compound of formula (V) is further allowed to be kept in the presence of an lw¾anrc o~r^
resulting compound is subjected to a reaction with a carboxy group-activating agent to activate the carboxy group therein.
The inorganic acid may be hydrochloride, nitric acid, sulfuric acid, phosphoric acid, or a mixture thereof, and the organic acid may be formic acid, acetic acid, tartaric acid, benzenesulfonic acid, toluenesulfonic acid, or a mixture thereof. In addition, exemplary carboxy group-activating agents include thionylchloride, oxalylchlori.de, phosphoryloxychloride, N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide (EDC), N,N'-dicyclohexylcarbodiimide (DCC), l,l"-carbonyldiimidazole (CDI), a mixture of DCC and 1- hydroxybenzotriazole (HOBt), a mixture of DCC and 1-hydroxysuccinimide, and a mixture thereof.
<Step 6>
In step 6, sitagliptin of formula (I) may be prepared by subjecting (3R)- 3-azido- 1 -(3-trifluoromethyl-5,6-dihydro-8H-[ 1 ,2,4]triazolo[4,3-a]pyrazin-7- yl)-4-(2,4,5-trifluorophenyl)-butan-l-one of formula (VI) obtained in step 5 to a reduction reaction with a reducing agent to reduce the azido group therein.
The reducing agent used in this reaction may be PPh3/H2O, PPh3/HCl, PPh3/NH4OH, PPh3/H2S, or a mixture thereof. Also, under the condition of the presence of a metal catalyst including Ranie-Ni, Pd, Pt, Pd/C, Pd/Al2O3, Pd(OH)2/C, and a mixture thereof, it may be used as the reducing agent hydrogen, HCOOH, (NH4)O2H, NH2NH2, BH3, NaBH4, Zn, HCl, or a mixture thereof.
The title compound, sitagliptin, thus obtained may be converted to a
form of phosphate through a further reaction with phosphoric acid.
A conventional sitagliptin preparation method requires a further purification of sitagliptin in order to improve both compound purity and optical purity, which disadvantageously causes a significant decrease of a yield. Unlike the conventional method, the inventive method employs as an intermediate an amine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric a^_(formula~(V)) which~can be formedin a high compound purity-(e . g . , 98%)- and a high optical purity (e.g., 99.8% ee), thereby simply and economically generating desired sitagliptin in a high yield and purity without an additional purification.
Further, the amine salt of formula (V) used as an intermediate in the preparation of sitagliptin according to the present invention is a novel compound.
Preferred amine salt intermediates include (R)-methylbenzylamine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (Va) and (S)- methylbenzylamine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid of formula (Vb):
In accordance with the method of the present invention, sitagliptin can be easily prepared in a high yield and purity.
The following Examples are intended to further illustrate the present invention without limiting its scope.
Example 1: Preparation of l-chloro-3-(2,4,5-trifluorophenyl)-(2S)-propanol
25g of 2,4,5-trifluorobenzene bromide was added dropwise to 75mL of tetrahydrofuran (THF) under a nitrogen atmosphere. The mixture was cooled to -20 °C and 60.4mL of 2M i-PrMgCl (in THF) was added thereto over 10 min while keeping the temperature of the mixture at 0-3 °C . The resulting solution was cooled to -10 °C for 1 hr with stirring and 1.8 lg of Cu(I)I was added thereto, which was further stirred at the same temperature for 30 min. Then, 13.9mL of (S)-epichlorohydrin diluted with 13.9mL of THF was added dropwise to the resulting solution for 30 min and stirred at -10 °C for 1.5 hrs, which was heated to 0 °C and further stirred for 1 hr. 250mL of 2N HC1 was added thereto and stirred at room temperature for 30 min. 125mL of dichloromethane (MC) was added to the resulting solution. The organic layer was separated, washed twice with 250mL of water, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 26.6g of the title compound (yield: 100%).
1H-NMR (300MHz, CDC13): 6 7.17-7.08 (1H, m), 6.96-6.88 (1H, m), 4.11-4.01 (1H, m), 3.66 (1H, dd, J=7.6, 11.3), 3.49 (1H, dd, 1=1.6, 11.3), 2.93-2.78 (2H, m), 2.39 (1H, d, J=5.3)
Example 2: Preparation of (2R)-l-(2,4,5-trifluorophenyl)-4-pent<
26.6g of l-chloro-3-(2,4,5-trifluorophenyl)-(2S)-propanol prepared in Example 1 and 53.2mL of methanol were mixed in a reactor with stirring. 35.6mL of 5N NaOH was slowly added thereto over 20 min and stirred for 15 min. After the completion of the reaction was confirmed by TLC, 266mL of H2O and 79.8mL of n-hexane were added thereto. The water layer was further extracted with 53.2mL of n-hexane. The combined organic layer was washed three~times w†tlrlO6TnI of water, dried"over'anhydrous"magnesmm sulfate and^ filtered using 133mL of n-hexane.
(Step 2-2)
66.5mL of THF was added to the filtrate obtained in Step 2-1 and cooled to -20 °C under a nitrogen atmosphere. 1.13g of Cu(I)I was added thereto, and 1.6M vinyl magnesium bromide (in THF) was slowly added to the resulting solution for 1 hr and further stirred for 30 min. After the completion of the reaction was confirmed by TLC, the reaction solution was heated to 0 °C . 266mL of 2N HCl was added thereto and stirred at room temperature for 30 min. The organic layer was separated, washed three times with 266mL of water, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 23.8g of the title compound (yield: 93%, purity: 95%, optical purity: 99.2% ee).
1H-NMR (300MHz, CDC13): δ 7.15-7.06 (1H, m), 6.94-6.86 (1H, m), 5.85-5.79 (1H, m), 5.20-5.14 (2H, m), 3.90-3.85 (1H, m), 3.82 (1H, dd, J=4.6, 18.5), 2.69 (lH, dd, J=7.9, 14.0), 2.37-2.32 (1H, m), 2.24-2.17 (1H, m), 1.86(lH, Br)
Example 3: Preparation of (2S)-l-(2-azido-4-pentenyl)-2,4,5- trifluorobenzene
23.98g of (2R)-l-(2,4,5-trifluorophenyl)-4-penten-2-ol prepared in Example 2 and 150mL of ethyl acetate were mixed in a reactor under a nitrogen atmosphere and cooled to 0°C . 16.59mL of triethylamine and 1.39g of 4- dimethylamino pyridine (DMAP) were sequentially added to the mixture, and 9.2 lmL of methanesulfonic acid was slowly added thereto over 15 min. After the completion of the reaction was confirmed by TLC, 240mL of water was added thereto. The organic layer was separated, sequentially washed with 24mL of IN HC1 and 120mL of water, washed twice with 240mL of brine, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure.
(Step 3-2)
The residue obtained in Step 3-1 was dissolved in 120mL of DMF, which was mixed with 9.58g of NaN3 dissolved in 36mL of water. The mixture was heated to 75 °C and stirred for 2 hrs. After the completion of the reaction was confirmed by TLC, the reaction solution was cooled to room temperature. 240mL of water and 120mL of n-hexane were added to the resulting solution. The organic layer was separated, washed twice with 240mL of water, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 25.3g of the title compound (yield: 94%).
1H-NMR (300MHz, CDC13): δ 7.11-7.02 (1H, m), 7.97-6.87 (1H, m), 5.89-5.80 (1H, m), 5.23-5.17 (1H, m), 3.63-3.59 (1H, m), 2.87 (1H, dd, J=4.7, 18.7), 2.68 (1H, dd, J=7.9, 13.7), 2.38-2.17 (2H, m)
Example 4: Preparation of (3R)-3-azido-4-(2,4,5-trifluorophenyI)-butyric acid
65.26g of potassium permanganate and 149mL of water were mixed in a reactor with stirring at room temperature. 149mL of acetone was added thereto, stirred for 30 min, and cooled to -20 °C . 24.9g of (2S)-l-(2-azido-4- pentenyl)-2,4,5-trifluorobenzene prepared in Example 3 dissolved in 74.5mL of acetone was slowly added to the mixture over 1 hr while keeping the temperature of the mixture at below -10 °C , which was stirred at -20 °C for 2 hrs. 500mL of 6N HC1 and 250mL of ethyl acetate (EA) were added to the resulting solution, and stirred for 1.5 hrs. The organic layer was separated and extracted with lOOmL of EA. The organic solvent was removed from the extract under a reduced pressure. The resulting resiude was dissolved in 250mL of EA, which was washed three times with 250mL of water. The organic layer was dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 26.2g of the title compound (yield: 98%, purity: 82%, optical purity: 96.6% ee).
1H-NMR (300MHz, CDC13): δ 10.5 (1H, br), 7.17-7.05 (1H, m),
7.02-6.87 (1H, m), 4.14-4.03 (1H, m), 2.94-2.78 (2H, m), 2.65-2.51 (2H, m)
Example 5: Preparation of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid (R)-methylbenzylamine salt
20g of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid prepared in Example 4 was added dropwise to 66.9mL of EA. 13.2mL of (R)- methylbenzylamine (MBA) was slowly added thereto over 15 min and stirred for 10 min. 214mL of n-hexane was slowly added to the resulting solution to generate a solid precipitate. After 1 hr, the precipitate was separated by filtration and dried with a warm breeze in a 40 °C oven for 12 hrs to obtain 22.0g of the title compound (yield: 75%, purity: 98%, optical purity: 99.8% ee).
1H-NMR (300MHz, CDC13): δ 7.61 (COOH, br), 7.39-7.28 (5H, m), 7.01-6.90 (2H, m), 4.25-4.18 (1H, m), 3.81-3.72 (1H, m), 2.69 (1H, dd, J=14.0, 4.8), 2.48 (1H, dd, J=14.0, 5.6), 2.08 (2H, d , J=6.7), 1.52 (3H, d, J=6.8) Example 6: Preparation of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid 2,2-diphenylethylamine salt
3.0g of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid (purity: 82%, optical purity: 96.6% ee) prepared in Example 4 was added dropwise to 21mL of EA. 2.28g of 2,2-diphenylethylamine was added thereto and stirred for 1 hr. The solid precipitate generated was separated by filtration and dried with a warm breeze in a 40 °C oven for 12 hrs to obtain 4.17g of the title compound (yield: 60%, purity: 98.8%, optical purity: 99.7% ee).
Ή-NMR (300MHz, CDC13): δ 7.34~7.03(10H, m), 7.17-7.01 (1H, m), 6.94~6.88(1H, m), 4.18 (1H, t), 3.95 (1H, m), 3.38 (2H, d, J=8.0), 2.83 (1H, dd, J=14.2, 5.1), 2.71 (1H, dd, J=14.2, 8.3), 2.33 (2H, m)
Example 7: Preparation of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid dibenz lamine salt
optical purity: 96.6% ee) prepared in Example 4 was added dropwise to 7.5mL of EA. 2.24mL of dibenzylamine was slowly added thereto over 15 min and stirred for 10 min. 22.5mL of n-hexane was slowly added to the resulting
solution to generate a solid precipitate. After 1 hr, the precipitate was separated by filtration and dried with a warm breeze in a 40 °C oven for 12 hrs to obtain 4.1g of the title compound (yield: 78%, purity: 98.5%, optical purity: 98.0% ee).
1H-NMR (300MHz, CDC13): δ 7.38-7.26 (10H, m), 7.17-7.01 (1H, m), 6.94-6.88 (1H, m), 4.00 (1H, m), 3.87 (4H, S), 2.85 (1H, dd, J-14.2, 5.2), 2.72 (1H, dd, J=14.2, 8.3), 2.42 (2H, d, J-7.1)
Example 8: Preparation of (3R)-3-azido-l-(3-trifluoromethyl-5,6-dihydro- 8H- [ 1 ,2,4] triazolo [4,3-a] py razin-7-yl)-4-(2,4,5-trifluor ophenyl)-butan-l -one
(Step 8-1)
31.2g of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid (R)- methylbenzylamine salt prepared in Example 5 was dissolved in 218mL of dichloromethane, and 156mL of 2N HC1 was added thereto and stirred. The organic layer was separated, washed three times with 312mL of water, dried over anhydrous magnesium sulfate, and filtered.
(Step 8-2)
12.0mL of thionyl chloride and 0.64mL of DMF were added to the resulting solution obtained in Step 8-1, which was refluxed for 3 hrs. After the completion of the reaction was confirmed by NMR, the remaining amouts of thionyl chloride and the organic solvent were removed from the resulting solution under a reduced pressure.
(Step 8-3)
The residue obtained in Step 8-2 was dissolved in lOOmL of MC, which was slowly added dropwise to 100ml of a saturated sodium bicarbonate solution
containing 1 1.4g of 3-trifluoromethyl-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3- ajpyrazine hydrochloride at below 10°C, and stirred at room temperature for 1 nr. The water layer was removed from the resulting solution. The organic layer was dried over anhydrous magnesium sulfate and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 33.8g of the title compound (yield: 95%).
1H-NMR (300MHz, CDC13): 67.20-7.11 (1H, m), 6.99~6.90(1H, m), 5.20-4.96 (2H, m), 4.28-4.05 (5H, m), 2.98-2.67 (4H, m)
Example 9: Preparation of sitagliptin
22.4g of triphenylphosphine and 336mL of THF were added to 33.6g of (3R)-3-azido-l-(3-trifluoromethyl-5,6-dihydro-8H-[l,2,4]triazolo[4,3-a] pyrazin-7-yl)-4-(2,4,5-trifluorophenyl)-butan-l-one prepared in Example 8, which was heated to 50 °C and stirred for 2 hrs. lOlmL of ammonia was added thereto and stirred for 10 hrs. THF was removed from the resulting solution under a reduced pressure. 168mL of 2N HC1 and 336mL of a mixed solvent of EA/n-hexane (5:3) were added to the resulting solution, and stirred, followed by layer separation. The water layer was washed three times with 336mL of a mixed solvent of EA/n-hexane (5:3). 16.8mL of ammonia was added to the water layer to neutralize it, which was extracted three times with 168mL of EA. The organic layer was dried over anhydrous magnesium sulfate and filtered. The organic solvent was removed from the filtrate under a reduced pressure to obtain 37.3g of the title compound (yield: 90%, purity: 99.7%, optical purity: 99.8% ee).
1H-NMR (300MHz, CDC13): δ 7.14-7.06 (1H, m), 7.00-6.88 (1H, m), 5.13-4.88 (2H, m), 4.24-3.80 (4H, m), 3.58 (1H, m), 2.85-2.66 (2H, m), 2.61-2.46 (2H, m), 2.1 1 (3H, br)
Example 10: Preparation of sitagliptin phosphate
17.5g of sitagliptin prepared in Example 9 was dissolved in a mixture of 220mL of IPA and 18mL of H2O. 5.6mL of phosphoric acid was slowly added to the resulting mixture, heated to 70 °C , stirred for 3 hrs, cooled to room temperature, and further stirred for 10 hrs. The solid precipitate generated was separated by filtration and dried with a warm breeze in a 40 °C oven for 12 hrs to obtain 20.3g of the title compound (yield: 95%).
Ή-NMR (300MHz, D2O): δ 7.23-7.10 (1H, m), 7.08-7.00 (1H, m), 4.88-4.78 (2H, m), 4.25-4.17 (2H, m), 3.97-3.89 (3H, m), 3.02-2.77 (4H, m)
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes of the invention also fall within the scope of the present invention defined by the claims that follow.
Claims
1. A method for preparing sitagliptin, which comprises the steps of:
(a) subjecting the compound of formula (IV) to a reaction with an amine of NR!R2R3 to obtain an amine salt of formula (V); and
(b) subjecting the amine salt of formula (V) to a condensation reaction with 3- trifluoromethyl-5,6,7,8-tetrahydro-[ 1 ,2,4]triazolo[4,3-a]pyrazine (TFT), followed by reduction of the azido group in the resulting compound:
R1 , R2 and R3 are each independently H, C1 -5 alkyl, benzyl, 1- phenylethyl, or 2,2-diphenylethyl; or linked together with the adjacent nitrogen atom to form a pyridine, piperidine, morpholine, pyrrolidine, or piperazine ring.
2. The method of claim 1, wherein the amine of NR!R2R3 used in step (a) is selected from the group consisting of benzylamine, (R)-methylbenzylamine, (S)-methylbenzylamine, 2,2-diphenylethylamine, dibenzylamine, dicyclohexylamine, diisopropylamine, diisopropylethylamine, diphenylamine, triethylamine, pyridine, and morpholine.
3. The method of claim 1, wherein in step (a), the amine of NR'R2R3 is used in an amount ranging from 0.8 to 10 mole equivalents based on the amount of the compound of formula (IV).
4. The method of claim 1, wherein in step (a), after the reaction with the amine, crystallization is performed in an organic solvent selected from the group consisting of toluene, ethylacetate, n-hexane, methylbutylether, heptane, and a mixture thereof.
5. The method of claim 1, wherein in step (b), the reduction is performed using a reducing agent selected from the group consisting of PPh3/H2O, PPh3/HCl, PPh3/NH4OH, PPh3/H2S, and a mixture thereof.
6. The method of claim 1, wherein the compound of formula (IV) is prepared by activating the hydroxy group of the compound of formula (II) and converting it to the azido group, followed by oxidation of the resulting compound.
7. The method of claim 6, wherein the activation of the hydroxy group of the compound of formula (II) is performed using an activating agent selected from the group consisting of mesyl chloride, />-tosyl chloride, benzenesulfonyl chloride, trifluoromethanesulfonyl chloride, and a mixture thereof.
8. The method of claim 6, wherein the oxidation is performed using an oxidizing agent selected from the group consisting of NaIO4, NaMn0 , KMnO4, H2CrO4, OsO4, NaOCl, and a mixture thereof.
9. The method of claim 6, wherein the compound of formula (II) is prepared by a method comprising the steps of:
(i) subjecting a 2,4,5-trifluorobenzene halide to organic metallization to obtain an organic metalide, and sequentially subjecting the organic metalide to respective reactions with a copper halide and (S)-epichlorohydrin; (ii) subjecting the resulting compound obtained in step (i) to an epoxidation reaction using a strong base in an organic solvent; and
(iii) subjecting the resulting compound obtained in step (ii) to a vinylation reaction with a vinyl magnesium halide.
10. The method of claim 9, wherein the reaction in step (iii) is conducted without removing the organic solvent used in step (ii).
1 1. The method of claim 9, wherein the strong base used in step (ii) is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, and a mixture thereof; the copper halide used in step (i) is selected from the group consisting of Cul, CuBr, CuBrS(CH3)2, and a mixture thereof; and the vinyl magnesium halide used in step (iii) is selected from the group consisting of vinyl magnesium bromide, vinyl magnesium chloride, and a mixture thereof.
12. A compound of formula (V):
R1, R2 and R3 are each independently H, C1-5 alkyl, benzyl, 1- phenylethyl, or 2,2-diphenylethyl; or linked together with the adjacent nitrogen atom to form a pyridine, piperidine, morpholine, pyrrolidine, or piperazine ring.
13. The compound of claim 12, which is (R)-methylbenzylamine salt or (S)- methylbenzylamine salt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100015273A KR101156587B1 (en) | 2010-02-19 | 2010-02-19 | Preparation method of sitagliptin and amine salt intermediate used therein |
KR10-2010-0015273 | 2010-02-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011102640A2 true WO2011102640A2 (en) | 2011-08-25 |
WO2011102640A3 WO2011102640A3 (en) | 2012-01-19 |
Family
ID=44483461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/001024 WO2011102640A2 (en) | 2010-02-19 | 2011-02-16 | Method for preparing sitagliptin and amine salt intermediates used therein |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101156587B1 (en) |
WO (1) | WO2011102640A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012046254A3 (en) * | 2010-10-08 | 2012-06-07 | Cadila Healthcare Limited | Process for preparing an intermediate of sitagliptin via enzymatic conversion |
CN102627648A (en) * | 2012-04-14 | 2012-08-08 | 江苏施美康药业有限公司 | Preparation method of sitagliptin |
EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
WO2013120465A1 (en) | 2012-02-16 | 2013-08-22 | Zentiva, K.S. | A process for the preparation of rivaroxaban based on the use of (s)-epichlorohydrin |
WO2014023930A1 (en) | 2012-08-08 | 2014-02-13 | Cipla Limited | Process for the preparation of sitagliptin and intermediate compounds |
US20140336196A1 (en) * | 2011-05-27 | 2014-11-13 | Merck Sharp & Dohme Corp. | Phosphoric acid salts of sitagliptin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
JO2625B1 (en) * | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
EP1909776A2 (en) * | 2005-07-25 | 2008-04-16 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
KR20070111099A (en) * | 2006-05-16 | 2007-11-21 | 영진약품공업주식회사 | Novel crystalline forms of cytagliptin hydrochloride, methods for their preparation and pharmaceutical compositions comprising the same |
KR101014885B1 (en) * | 2008-07-09 | 2011-02-15 | 강원대학교산학협력단 | Method for preparing allylbenzene derivative using palladium and ligand |
KR101222679B1 (en) * | 2009-10-21 | 2013-01-16 | 한미사이언스 주식회사 | Method of preparing sitagliptin and intermediates used therein |
-
2010
- 2010-02-19 KR KR1020100015273A patent/KR101156587B1/en not_active Expired - Fee Related
-
2011
- 2011-02-16 WO PCT/KR2011/001024 patent/WO2011102640A2/en active Application Filing
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012046254A3 (en) * | 2010-10-08 | 2012-06-07 | Cadila Healthcare Limited | Process for preparing an intermediate of sitagliptin via enzymatic conversion |
CN103228658A (en) * | 2010-10-08 | 2013-07-31 | 卡迪拉保健有限公司 | Process for preparing an intermediate of sitagliptin via enzymatic conversion |
US20140336196A1 (en) * | 2011-05-27 | 2014-11-13 | Merck Sharp & Dohme Corp. | Phosphoric acid salts of sitagliptin |
EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
WO2013104774A1 (en) | 2012-01-12 | 2013-07-18 | Lek Pharmaceuticals D.D. | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF |
WO2013120465A1 (en) | 2012-02-16 | 2013-08-22 | Zentiva, K.S. | A process for the preparation of rivaroxaban based on the use of (s)-epichlorohydrin |
CN102627648A (en) * | 2012-04-14 | 2012-08-08 | 江苏施美康药业有限公司 | Preparation method of sitagliptin |
WO2014023930A1 (en) | 2012-08-08 | 2014-02-13 | Cipla Limited | Process for the preparation of sitagliptin and intermediate compounds |
US9233967B2 (en) | 2012-08-08 | 2016-01-12 | Cipla Limited | Process for the preparation of sitagliptin and intermediate compounds |
Also Published As
Publication number | Publication date |
---|---|
KR101156587B1 (en) | 2012-06-20 |
KR20110095672A (en) | 2011-08-25 |
WO2011102640A3 (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101222679B1 (en) | Method of preparing sitagliptin and intermediates used therein | |
WO2011102640A2 (en) | Method for preparing sitagliptin and amine salt intermediates used therein | |
JP7377828B2 (en) | Method for preparing pyrimidinylcyclopentane compounds | |
EP2609099A2 (en) | Sitagliptin, salts and polymorphs thereof | |
JP2000516934A (en) | Stereoselective method for producing 4-acetoxyazetidinone | |
JP2016503389A (en) | Process for the preparation of (1S, 4S, 5S) -4-bromo-6-oxabicyclo [3.2.1] octan-7-one | |
EP2861598A1 (en) | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ß-AMINOBUTYRYL SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,4]DIAZOLO[4,3-alpha]PYRAZIN-7-YL COMPOUNDS | |
KR20160008873A (en) | Novel beta-sulfinamino malonate derivatives and process for preparing the same, and process for preparing sitagliptin using the same | |
JP4187822B2 (en) | Process for producing optically active 4-hydroxy-2-pyrrolidone | |
JP2002338574A (en) | Method for producing piperidylidene derivative having physiological activity | |
JP2004026736A (en) | Optically active amino acid derivative and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11744882 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11744882 Country of ref document: EP Kind code of ref document: A2 |